Table 1.
Latency of Epstein-Barr virus (EBV)-positive lymphomas developing in immunocompetent hosts.
| Lymphoma | EBV frequency (%) | Latency |
|---|---|---|
| Hodgkin’s disease | ~40 | II |
| Non-Hodgkin’s lymphomas | ||
| Burkitt’s lymphoma | 20–95 | I |
| Diffuse large B-cell lymphoma and CD30+ Ki-1+ anaplastic large cell lymphoma | 10–35 | II |
| Lymphatoid granulomatosis | 80–95 | II |
| T-cell-rich B-cell lymphoma | 20 | II |
| Angioimmunoblastic lymphoma | >80 | II |
| Extranodal NK/T-cell lymphoma, nasal type | >95 | II |
| Agressive NK/T leukaemia/lymphoma | 30–60 | II or I |
NK, natural killer.